Odylia Therapeutics CSO, Ashley Winslow, and Director of Development, Heather Greene, discuss Odylia’s RPGRIP1 Gene Therapy program to treat vision loss in patients diagnosed with Leber Congenital Amaurosis 6 (LCA6). Follow the link to view a recording of the webinar.
The challenges of bringing gene therapy treatments for rare disease to clinical trial, World Orphan Drug Congress Europe 2020, Scott Dorfman, CEO
Exploring Innovative Partnerships to Enable Gene Therapy Manufacturing for Rare Ocular Disorders, Gene Therapy for Ophthalmic Disorders 2020- Ashley Winslow, CSO
PANEL DISCUSSION: Evaluating the Current Commercial Landscape in Light of a Recent Ophthalmic Approval, Gene Therapy for Ophthalmic Disorders 2020- Ashley Winslow, CSO
Sharing Insight for Gene Therapy Manufacturing, The NIH and FDA Workshop on Expanding AAV Manufacturing Capacity for Rare Disease Gene Therapies, Scott Dorfman, CEO